aspirin + clopidogrel + policosanol

This combination therapy consists of standard dual antiplatelet therapy (DAPT)—comprising the cyclooxygenase-1 (COX-1) inhibitor aspirin and the P2Y12 purinoceptor antagonist clopidogrel—supplemented with policosanol, a natural mixture of long-chain aliphatic alcohols derived from sugar cane wax. Developed and evaluated by Shenyang Northern Hospital (General Hospital of Northern Theater Command), this regimen is specifically investigated for patients with coronary artery disease (CAD) who exhibit high on-treatment platelet reactivity (HPR) following percutaneous coronary intervention (PCI). Policosanol acts as an adjunct antiplatelet agent, potentially reducing platelet aggregation through pathways involving thromboxane inhibition and HMG-CoA reductase modulation, thereby addressing clopidogrel resistance without significantly increasing bleeding risks compared to standard DAPT.

Other names

dual antiplatelet-Shenyang Northern Hospital-coronary artery diseasepolicosanol plus dual antiplatelet therapypolicosanol combination therapy